Xevinapant

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameXevinapant
Drug Alias NameXevinapanAT-406Debio-1143SM-406
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionInhibitor of apoptosis protein 3 inhibitorscIAP1/cIAP2 inhibitors
TargetsInhibitor of apoptosis protein 3cIAP1/cIAP2
Therapy Area/IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oral Squamous Cell CarcinomaSolid tumours +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAscentaMerck Serono
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyMemorial Sloan Kettering Cancer CenterMerck Healthcare Kgaa +[7] 
Inactive CompaniesEmd Serono IncEmd Serono Research & Development Institute IncGroupe Oncologie Radiotherapie Tete Et Cou +[9] 
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOropharyngeal Neoplasms +[7] 
Inactive IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oral Squamous Cell CarcinomaHypopharyngeal Neoplasms +[13] 

Other Information

ATC CodeN/A
Related LinksN/A